Harwin Peter Evan's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Jun 23, 2026
- Accession no.
- 0001104659-26-076967
- Filed
- Jun 23, 2026, 9:56 PM ET
- Trade date
- Jun 23, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $399.7M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director |
| Fairmount Funds Management LLCCIK 0001802528 | Director |
| Kiselak TomasCIK 0001830177 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | Common Stock | CConversionAcquired | +666,680 | – | – | 4,684,781 | Indirect | |
| Jun 23, 2026 | Common Stock | SSaleDisposed | −4,684,781 | $85.31 | −$399,658,667.11 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | Common Stock | CConversionDisposed | −666,680 | $0.00 | $0 | 0 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.